Pan Cancer T Raises EUR 10 Million To Launch First-In-Human TCR-T Therapy Trial For Triple-Negative Breast Cancer

The funding comprises EUR 5 million from existing investors Van Herk Ventures, Thuja Capital, Erasmus MC O&O Holdings, and InnovationQuarter along with a EUR 5 million Innovation Credit loan from the Dutch Ministry of Economic Affairs. The financing will support treatment of TNBC patients at leading cancer centres across the Netherlands.

“Our mission is to empower a patient’s own immune cells to tackle hard-to-treat cancers like TNBC”, said Rachel Abbott, Chief Executive Officer of Pan Cancer T. “This significant investment marks a pivotal moment as we transition from preclinical validation to treating patients with our first novel T-cell receptor (TCR) T cell therapy, PCT1:CO-STIM, following our planned regulatory filing with the EMA in 2026. We are deeply grateful to our investors and the Netherlands Enterprise Agency (RVO) for their confidence in our approach.”

Read Also - Swedish Biotech Melt&Marble Secures €7M For Food And Beauty Fat Innovation

“Thuja Capital is dedicated to investing in the most innovative life sciences companies. Pan Cancer T’s TCR-T platform addresses hard-to-treat solid tumours, such as TNBC, that are the greatest challenge in oncology. Following our recent success in the cell and gene therapy field, with AstraZeneca’s acquisition of our portfolio company EsoBiotec, we are delighted to continue backing another pioneer in the C&GT space,” said Michel Briejer, Managing Partner at Thuja Capital and member of Pan Cancer T’s Supervisory Board.

The upcoming trial will evaluate the safety, tolerability, and preliminary efficacy of PCT1:CO-STIM in TNBC patients, a group facing urgent unmet medical needs, with a 5-year survival rate after metastatic progression of just 12% and a median overall survival under six months.

PCT1:CO-STIM is being developed as an autologous T cell therapy, with potential for in vivo delivery in the future. It incorporates a proprietary TCR targeting ROPN1, a tumour-restricted antigen present in over 90% of TNBC and melanoma cases.

The therapy also features a unique co-stimulatory technology designed to overcome immune resistance in solid tumours, aiming to provide durable responses for patients with limited treatment options.

About Pan Cancer T

Pan Cancer T is developing next-generation TCR-T cell therapies for hard-to-treat solid tumours, including triple-negative breast cancer and cancers of the skin, colorectum, stomach, oesophagus, ovary, and uterus. Founded in 2020 as an Erasmus MC spin-out, the company has raised €21 million from investors and grants to date.